SAN MATEO, Calif.--(BUSINESS WIRE)--Afferent Pharmaceuticals, a leader in the development of small molecule compounds for the treatment of poorly managed and common neurogenic disorders, announced today that it will present four papers at the upcoming American Thoracic Society (ATS) 2016 International Conference, to be held May 13-18, 2016 in San Francisco. The abstracts will cover clinical and preclinical data related to AF-219 and AF-130, the company’s orally available, first-in-class compounds that selectively block P2X3 receptors.
Chronic Cough-Related Presentations
Profound Antitussive Response to P2X3 Blockade with AF-219 Permits Correlation of Objective Measure of Cough with Improvement in Patient Reported Outcomes
Session: B14: High-Impact Late-Breaking Clinical Trials (Mini-symposium)
Date and time: Monday, May 16, 2016 10-10:15 am
A Phase 2 Dose-Escalation Study with AF-219, a P2X3 Antagonist for the Treatment of Chronic Cough
Session: D23 - Symptoms Matter: Cough, Dyspnea, Fatigue and Quality of Life (Poster discussion)
Date and time: Wednesday, May 18, 2016, 9:00-11:00 am
Purinergic P2X3 Receptor Signalling in the Carotid Body (CB) Accounts for Its Aberrant Discharge in Pathology Revealing New Therapeutic Target for Hypertension
Session: B64 – Bop Goes the Heart: Cardiovascular Consequences of SDB (Thematic poster)
Date and time: Monday, May 16, 2016, 9:00 am-4:15 pm
Carotid Body Involvement in a Translational Ovine Model of Renovascular Hypertension: Sensitivity to Purinergic P2X3 Receptor Antagonism with AF-130
Session: D29 – Bench to Bedside: Translational Science in SDB (Poster discussion)
Date and time: Wednesday, May 18, 2016, 9:00-11:00 AM
About P2X3 Receptor-Mediated Sensitization
P2X3 receptors play a key role in the sensitization of certain sensory nerves, notably C-fiber afferents. These nerves become activated and sensitized under pathologic conditions mediated by a common signal, ATP, when it is released in high concentrations due to cellular distress following injury or infection. Afferent’s compounds, AF-219 and AF-130, selectively block ATP activation of P2X3 channels, reducing a range of pathologic sensory signs and symptoms.
P2X3 receptor-mediated sensitization has been implicated in inflammatory, visceral and neuropathic pain states, as well as airways hyperreactivity, treatment-resistant hypertension, heart failure, migraine, itch and cancer pain.
About Afferent Pharmaceuticals
Afferent Pharmaceuticals is a clinical-stage biotechnology company and a leader in the development of novel drugs for the treatment of a range of neurogenic conditions. These conditions affect millions of patients who suffer from chronic respiratory and urologic sensory pathologies, as well as chronic pain and cardiovascular disorders, and who have limited, if any, treatment options. These chronic pathologies arise when certain nerves become hyper-sensitized as a result of inflammation, distress, infection or tissue injury, which may remain chronically sensitized for months and even years.
Afferent is developing a portfolio of compounds that selectively block P2X3, which plays a key role in the sensitization of these nerves. Afferent’s lead molecule, AF-219, is in Phase 2 clinical development for the treatment of pathologic cough, including chronic cough and cough in idiopathic pulmonary fibrosis (IPF) patients. A second compound, AF-130, is in Phase 1 clinical testing and will be evaluated in a number of non-respiratory conditions. For more information on the company, please visit Afferent’s website at www.afferentpharma.com.